PRELUDE THERAPEUTICS INC Increase (Decrease) in Prepaid Expense and Other Assets
PRELUDE THERAPEUTICS INC (PRLD) reported Increase (Decrease) in Prepaid Expense and Other Assets of $663.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $102.00K, a 69.18% decline year-over-year.
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $561.00K, a 46.47% decline year-over-year.
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$895.00K.
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$287.00K.
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for fiscal 2025 was $197.00K.
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$373.00K, a 225.59% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for fiscal 2023 was $297.00K, a 92.27% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.84M, a 178.08% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $663.00K 10-Q · filed 2026-08-11 | -$232.00K derived: sum of 3 quarters · filed 2026-08-11 | -$519.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $561.00K 10-Q · filed 2026-05-12 | -$334.00K derived: sum of 2 quarters · filed 2026-05-12 | -$621.00K derived: sum of 3 quarters · filed 2026-05-12 | -$290.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$895.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.18M derived: sum of 2 quarters · filed 2026-03-10 | -$851.00K derived: sum of 3 quarters · filed 2026-08-11 | $197.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$287.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $44.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.09M 10-Q · filed 2025-11-12 | $612.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.38M 10-Q · filed 2026-08-11 | $899.00K derived: sum of 3 quarters · filed 2026-08-11 | $790.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.05M 10-Q · filed 2026-05-12 | $568.00K derived: sum of 2 quarters · filed 2026-05-12 | $459.00K derived: sum of 3 quarters · filed 2026-05-12 | -$113.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$589.00K derived: sum of 2 quarters · filed 2026-03-10 | -$1.16M derived: sum of 3 quarters · filed 2026-03-10 | -$373.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$681.00K derived: sum of 2 quarters · filed 2025-11-12 | $107.00K 10-Q · filed 2025-11-12 | -$1.65M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$572.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $216.00K 10-Q · filed 2025-08-14 | -$1.54M derived: sum of 3 quarters · filed 2025-08-14 | -$2.03M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $788.00K 10-Q · filed 2025-05-06 | -$968.00K derived: sum of 2 quarters · filed 2025-05-06 | -$1.46M derived: sum of 3 quarters · filed 2025-05-06 | $730.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$2.24M derived: sum of 2 quarters · filed 2025-03-10 | -$58.00K derived: sum of 3 quarters · filed 2025-03-10 | $297.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | -$487.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.70M derived: sum of 2 quarters · filed 2024-11-06 | $2.05M 10-Q · filed 2024-11-06 | $2.31M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.54M 10-Q · filed 2024-08-12 | $2.79M derived: sum of 3 quarters · filed 2024-08-12 | $7.94M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $355.00K 10-Q · filed 2024-05-07 | $607.00K derived: sum of 2 quarters · filed 2024-05-07 | $5.75M derived: sum of 3 quarters · filed 2024-05-07 | $4.29M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $5.40M derived: sum of 2 quarters · filed 2024-02-15 | $3.94M derived: sum of 3 quarters · filed 2024-02-15 | $3.84M 10-K · filed 2024-02-15 |
| 2022-09-30 | $5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $3.68M derived: sum of 2 quarters · filed 2023-11-01 | $3.59M 10-Q · filed 2023-11-01 | $2.44M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.56M 10-Q · filed 2023-08-03 | -$2.71M derived: sum of 3 quarters · filed 2023-08-03 | $869.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$93.00K 10-Q · filed 2023-05-08 | -$1.24M derived: sum of 2 quarters · filed 2023-05-08 | $2.33M derived: sum of 3 quarters · filed 2023-05-08 | $2.05M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.43M derived: sum of 2 quarters · filed 2023-03-15 | $2.14M derived: sum of 3 quarters · filed 2023-03-15 | $1.38M 10-K · filed 2023-03-15 |
| 2021-09-30 | $3.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $3.29M derived: sum of 2 quarters · filed 2022-11-14 | $2.53M 10-Q · filed 2022-11-14 | $1.76M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$283.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.04M 10-Q · filed 2022-08-09 | -$1.81M derived: sum of 3 quarters · filed 2022-08-09 | $475.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$761.00K 10-Q · filed 2022-05-10 | -$1.53M derived: sum of 2 quarters · filed 2022-05-10 | $758.00K derived: sum of 3 quarters · filed 2022-05-10 | $830.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.52M derived: sum of 2 quarters · filed 2022-03-17 | $1.59M derived: sum of 3 quarters · filed 2022-03-17 | $1.16M 10-K · filed 2022-03-17 |
| 2020-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.36M derived: sum of 2 quarters · filed 2021-11-12 | $1.92M 10-Q · filed 2021-11-12 | $2.92M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$364.00K 10-Q · filed 2021-08-12 | $637.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$436.00K 10-Q · filed 2021-05-11 | $565.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.34M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $344.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |